{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:05:40Z","timestamp":1790701540817,"version":"4.1.0"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014389","name":"Amarin Pharma Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014389","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014384","name":"Amarin Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014384","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal Plus: Cardiology Research and Practice"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.ahjo.2026.100897","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T06:39:35Z","timestamp":1789540775000},"page":"100897","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Barrier identification and strategic design for hypertriglyceridemia management in the post-acute coronary syndrome patient population at a large integrated health system"],"prefix":"10.1016","volume":"70","author":[{"given":"Zachary M.","family":"Salvati","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole L.","family":"Walters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Brangan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Keiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Johns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Voyce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciano","family":"Kolodny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sephy","family":"Philip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laney K.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott A.","family":"LeMaire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"deRichemond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahjo.2026.100897_bb0005","doi-asserted-by":"crossref","first-page":"617","DOI":"10.2147\/VHRM.S37119","article-title":"Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes","volume":"9","author":"Kones","year":"2013","journal-title":"Vasc. Health Risk Manag."},{"issue":"9943","key":"10.1016\/j.ahjo.2026.100897_bb0010","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S0140-6736(14)61177-6","article-title":"Triglycerides and cardiovascular disease","volume":"384","author":"Nordestgaard","year":"2014","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.ahjo.2026.100897_bb0015","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1161\/CIRCRESAHA.115.306249","article-title":"Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease","volume":"118","author":"Nordestgaard","year":"2016","journal-title":"Circ. Res."},{"key":"10.1016\/j.ahjo.2026.100897_bb0020","doi-asserted-by":"crossref","DOI":"10.1177\/11795468241291640","article-title":"Two sides of triglycerides in atherogenesis: an essential contributor","volume":"19","author":"Poznyak","year":"2025","journal-title":"Clin. Med. Insights Cardiol."},{"issue":"6","key":"10.1016\/j.ahjo.2026.100897_bb0025","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.jacl.2023.09.004","article-title":"Remnant cholesterol predicts cardiovascular mortality beyond low-density lipoprotein cholesterol in patients with peritoneal dialysis","volume":"17","author":"Guo","year":"2023","journal-title":"J. Clin. Lipidol."},{"issue":"1","key":"10.1016\/j.ahjo.2026.100897_bb0030","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1016\/j.jacl.2023.11.004","article-title":"Characteristics and prognosis of patients with elevated triglycerides in acute myocardial infarction: observational data from a large database over a 17-year period","volume":"18","author":"Zeller","year":"2024","journal-title":"J. Clin. Lipidol."},{"issue":"8_Supplement","key":"10.1016\/j.ahjo.2026.100897_bb0035","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/S0735-1097(23)02204-0","article-title":"Management of elevated triglyceride levels in patients following acute coronary syndrome: real-world results from a large integrated healthcare system","volume":"81","author":"Shuey","year":"2023","journal-title":"JACC"},{"issue":"5","key":"10.1016\/j.ahjo.2026.100897_bb0040","first-page":"1256","article-title":"Treatment of severe hyperlipidemia and associated cardiovascular outcomes: data from a large healthcare system","volume":"19","author":"Hallihan","year":"2025","journal-title":"J. Clin. Lipidol."},{"issue":"25","key":"10.1016\/j.ahjo.2026.100897_bb0045","first-page":"e1082","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.ahjo.2026.100897_bb0050","doi-asserted-by":"crossref","first-page":"133608","DOI":"10.1016\/j.ijcard.2025.133608","article-title":"Prevalence of hypertriglyceridemia and its association with extreme cardiovascular risk in patients with acute and chronic coronary syndrome enrolled in a cardiac rehabilitation program","volume":"439","author":"Tognola","year":"2025","journal-title":"Int. J. Cardiol."},{"issue":"6","key":"10.1016\/j.ahjo.2026.100897_bb0055","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.jacl.2019.10.014","article-title":"National Lipid Association Scientific Statement on the use of icosapent ethyl in statin-treated patients with elevated triglycerides and high or very-high ASCVD risk","volume":"13","author":"Orringer","year":"2019","journal-title":"J. Clin. Lipidol."},{"issue":"1","key":"10.1016\/j.ahjo.2026.100897_bb0060","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.ahjo.2026.100897_bb0065","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.jacc.2021.06.011","article-title":"2021 ACC expert consensus decision pathway on the management of ASCVD risk reduction in patients with persistent hypertriglyceridemia: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"78","author":"Virani","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"issue":"17","key":"10.1016\/j.ahjo.2026.100897_bb0070","first-page":"e1154","article-title":"ACC\/AHA\/AACVPR\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of dyslipidemia: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"153","author":"Blumenthal","year":"2026","journal-title":"Circulation"},{"issue":"13","key":"10.1016\/j.ahjo.2026.100897_bb0075","first-page":"e771","article-title":"2025 ACC\/AHA\/ACEP\/NAEMSP\/SCAI guideline for the management of patients with acute coronary syndromes: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"151","author":"Rao","year":"2025","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.ahjo.2026.100897_bb0080","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: the Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)","volume":"41","author":"Mach","year":"2020","journal-title":"Eur. Heart J."},{"issue":"6","key":"10.1016\/j.ahjo.2026.100897_bb0085","doi-asserted-by":"crossref","DOI":"10.1111\/dme.70030","article-title":"Optimisation of care among patients with diabetes mellitus and acute coronary syndrome through a specialised cardiodiabetes service\u2014a registry study","volume":"42","author":"Shah","year":"2025","journal-title":"Diabet. Med."},{"issue":"18","key":"10.1016\/j.ahjo.2026.100897_bb0095","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.2146\/ajhp161061","article-title":"Medication therapy disease management: Geisinger\u2019s approach to population health management","volume":"74","author":"Jones","year":"2017","journal-title":"Am. J. Health Syst. Pharm."},{"issue":"4","key":"10.1016\/j.ahjo.2026.100897_bb0100","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1007\/s11606-023-08500-0","article-title":"The role of human-centered design in healthcare innovation: a digital health equity case study","volume":"39","author":"Levander","year":"2024","journal-title":"J. Gen. Intern. Med."},{"issue":"Suppl 3(3)","key":"10.1016\/j.ahjo.2026.100897_bb0105","doi-asserted-by":"crossref","first-page":"S230","DOI":"10.1097\/QAI.0000000000002216","article-title":"Human-centered design lessons for implementation science: improving the implementation of a patient-centered care intervention","volume":"82","author":"Beres","year":"2019","journal-title":"J. Acquir. Immune Defic. Syndr."},{"issue":"1","key":"10.1016\/j.ahjo.2026.100897_bb0110","doi-asserted-by":"crossref","DOI":"10.1186\/1748-5908-9-39","article-title":"Expert recommendations for implementing change (ERIC): protocol for a mixed methods study","volume":"9","author":"Waltz","year":"2014","journal-title":"Implement. Sci."},{"issue":"1","key":"10.1016\/j.ahjo.2026.100897_bb0115","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s13012-017-0635-3","article-title":"Psychometric assessment of three newly developed implementation outcome measures","volume":"12","author":"Weiner","year":"2017","journal-title":"Implement. Sci."},{"issue":"2","key":"10.1016\/j.ahjo.2026.100897_bb0120","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)\u2014a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J. Biomed. Inform."},{"issue":"2","key":"10.1016\/j.ahjo.2026.100897_bb0125","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s10488-010-0319-7","article-title":"Outcomes for implementation research: conceptual distinctions, measurement challenges, and research agenda","volume":"38","author":"Proctor","year":"2011","journal-title":"Admin. Pol. Ment. Health"},{"key":"10.1016\/j.ahjo.2026.100897_bb0130","series-title":"The Coding Manual for Qualitative Researchers","author":"Saldana","year":"2021"},{"key":"10.1016\/j.ahjo.2026.100897_bb0135","series-title":"ATLAS.ti (Version 8.4.15.0)","author":"ATLAS.ti Scientific Software Development GmbH","year":"2023"},{"issue":"1","key":"10.1016\/j.ahjo.2026.100897_bb0140","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s43058-023-00424-4","article-title":"A picture is worth a thousand words: advancing the use of visualization tools in implementation science through process mapping and matrix heat mapping","volume":"4","author":"Salvati","year":"2023","journal-title":"Implement. Sci. Commun."},{"issue":"9","key":"10.1016\/j.ahjo.2026.100897_bb0145","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.sapharm.2021.01.001","article-title":"Measuring implementation of medication optimization services: development and validation of an implementation outcomes questionnaire","volume":"17","author":"Livet","year":"2021","journal-title":"Res. Soc. Adm. Pharm."},{"issue":"6","key":"10.1016\/j.ahjo.2026.100897_bb0150","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1093\/intqhc\/mzm042","article-title":"Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups","volume":"19","author":"Tong","year":"2007","journal-title":"Int. J. Qual. Health Care"},{"issue":"1","key":"10.1016\/j.ahjo.2026.100897_bb0155","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s13012-016-0538-8","article-title":"Behavior change interventions and policies influencing primary healthcare professionals\u2019 practice\u2014an overview of reviews","volume":"12","author":"Chauhan","year":"2017","journal-title":"Implement. Sci."},{"issue":"1","key":"10.1016\/j.ahjo.2026.100897_bb0160","doi-asserted-by":"crossref","DOI":"10.1080\/28338073.2024.2363550","article-title":"Impact of educational activity formats, online or in-person, on the intention of medical specialists to adopt a clinical behaviour: a comparative study","volume":"13","author":"Ayivi-Vinz","year":"2024","journal-title":"J. CME"},{"key":"10.1016\/j.ahjo.2026.100897_bb0165","doi-asserted-by":"crossref","first-page":"134046","DOI":"10.1016\/j.ijcard.2025.134046","article-title":"Eligibility for icosapent ethyl in patients undergoing cardiac rehabilitation: a real-world cohort study","volume":"445","author":"Brucato","year":"2026","journal-title":"Int. J. Cardiol."},{"issue":"17","key":"10.1016\/j.ahjo.2026.100897_bb0170","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus","volume":"362","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"21","key":"10.1016\/j.ahjo.2026.100897_bb0175","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1056\/NEJMoa2210645","article-title":"Triglyceride lowering with pemafibrate to reduce cardiovascular risk","volume":"387","author":"Pradhan","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ahjo.2026.100897_bb0180","author":"Regulations.gov"},{"issue":"9567","key":"10.1016\/j.ahjo.2026.100897_bb0185","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S0140-6736(07)60527-3","article-title":"Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis","volume":"369","author":"Yokoyama","year":"2007","journal-title":"Lancet"},{"issue":"8_Supplement","key":"10.1016\/j.ahjo.2026.100897_bb0190","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/S0735-1097(23)01557-7","article-title":"Benefits of icosapent ethyl in patients with recent acute coronary syndrome (ACS): REDUCE-IT ACS","volume":"81","author":"Steg","year":"2023","journal-title":"J. Am. Coll. Cardiol."},{"issue":"5","key":"10.1016\/j.ahjo.2026.100897_bb0195","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.124.038656","article-title":"Cardiovascular outcomes with icosapent ethyl by baseline low-density lipoprotein cholesterol: a secondary analysis of the REDUCE-IT randomized trial","volume":"14","author":"Aggarwal","year":"2025","journal-title":"J. Am. Heart Assoc."},{"issue":"Supplement_2","key":"10.1016\/j.ahjo.2026.100897_bb0200","article-title":"Cost-effectiveness of icosapent ethyl for primary and secondary cardiovascular prevention in the UK","volume":"43","author":"Michaeli","year":"2022","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ahjo.2026.100897_bb0205","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2023.1220017","article-title":"Global eligibility and cost effectiveness of icosapent ethyl in primary and secondary cardiovascular prevention","volume":"10","author":"Toth","year":"2023","journal-title":"Front. Cardiovasc. Med."},{"issue":"1","key":"10.1016\/j.ahjo.2026.100897_bb0210","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1080\/13696998.2025.2557717","article-title":"Cost-utility analysis of icosapent ethyl in patients with high triglyceride levels and recent acute coronary syndrome in Catalonia","volume":"28","author":"Comin-Colet","year":"2025","journal-title":"J. Med. Econ."}],"container-title":["American Heart Journal Plus: Cardiology Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666602226001862?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666602226001862?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:35:17Z","timestamp":1790699717000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666602226001862"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":41,"alternative-id":["S2666602226001862"],"URL":"https:\/\/doi.org\/10.1016\/j.ahjo.2026.100897","relation":{},"ISSN":["2666-6022"],"issn-type":[{"value":"2666-6022","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Barrier identification and strategic design for hypertriglyceridemia management in the post-acute coronary syndrome patient population at a large integrated health system","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal Plus: Cardiology Research and Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahjo.2026.100897","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100897"}}